CBS/PSP Sleep Disorders Management

CBS/PSP Sleep Disorders Management

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CBS/PSP Sleep Disorders Management</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">Total Sleep Time</td>
<td>Reduced (280-320 min)</td>
</tr>
<tr>
<td class="label">Sleep Efficiency</td>
<td>65-75%</td>
</tr>
<tr>
<td class="label">REM Sleep %</td>
<td>8-15%</td>
</tr>
<tr>
<td class="label">NREM N3 %</td>
<td>10-18%</td>
</tr>
<tr>
<td class="label">Sleep Latency</td>
<td>Prolonged (45-60 min)</td>
</tr>
<tr>
<td class="label">REM Latency</td>
<td>May be normal or prolonged</td>
</tr>
<tr>
<td class="label">Arousal Index</td>
<td>Elevated (15-25/hr)</td>
</tr>
<tr>
<td class="label">Assessment</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Polysomnography (PSG)</td>
<td>Gold standard for sleep architecture, RBD, sleep apnea</td>
</tr>
<tr>
<td class="label">Actigraphy</td>
<td>2-week sleep-wake pattern, circadian rhythm</td>
</tr>
<tr>
<td class="label">MSLT</td>
<td>Daytime sleepiness, narcolepsy</td>
</tr>
<tr>
<td class="label">Home Sleep Apnea Test</td>
<td>Screen for obstructive sleep apnea</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Implementation</td>
</tr>
<tr>
<td class="label">Consistent schedule</td>
<td>Same bedtime/wake time ± 30 min daily</td>
</tr>

CBS/PSP Sleep Disorders Management

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">CBS/PSP Sleep Disorders Management</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>CBS</td>
</tr>
<tr>
<td class="label">Total Sleep Time</td>
<td>Reduced (280-320 min)</td>
</tr>
<tr>
<td class="label">Sleep Efficiency</td>
<td>65-75%</td>
</tr>
<tr>
<td class="label">REM Sleep %</td>
<td>8-15%</td>
</tr>
<tr>
<td class="label">NREM N3 %</td>
<td>10-18%</td>
</tr>
<tr>
<td class="label">Sleep Latency</td>
<td>Prolonged (45-60 min)</td>
</tr>
<tr>
<td class="label">REM Latency</td>
<td>May be normal or prolonged</td>
</tr>
<tr>
<td class="label">Arousal Index</td>
<td>Elevated (15-25/hr)</td>
</tr>
<tr>
<td class="label">Assessment</td>
<td>Purpose</td>
</tr>
<tr>
<td class="label">Polysomnography (PSG)</td>
<td>Gold standard for sleep architecture, RBD, sleep apnea</td>
</tr>
<tr>
<td class="label">Actigraphy</td>
<td>2-week sleep-wake pattern, circadian rhythm</td>
</tr>
<tr>
<td class="label">MSLT</td>
<td>Daytime sleepiness, narcolepsy</td>
</tr>
<tr>
<td class="label">Home Sleep Apnea Test</td>
<td>Screen for obstructive sleep apnea</td>
</tr>
<tr>
<td class="label">Strategy</td>
<td>Implementation</td>
</tr>
<tr>
<td class="label">Consistent schedule</td>
<td>Same bedtime/wake time ± 30 min daily</td>
</tr>
<tr>
<td class="label">Sleep environment</td>
<td>Cool (65-68°F), dark, quiet</td>
</tr>
<tr>
<td class="label">Blue light restriction</td>
<td>No screens 1-2 hours before bed</td>
</tr>
<tr>
<td class="label">Caffeine restriction</td>
<td>No caffeine after 12 PM</td>
</tr>
<tr>
<td class="label">Alcohol restriction</td>
<td>No alcohol within 3 hours of bedtime</td>
</tr>
<tr>
<td class="label">Exercise timing</td>
<td>Morning/afternoon; avoid evening</td>
</tr>
<tr>
<td class="label">Bedroom use</td>
<td>Reserve bed for sleep only</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>0.5-10 mg HS</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>25-100 mg HS</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>100-600 mg HS</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>0.25-1 mg HS</td>
</tr>
<tr>
<td class="label">Ramelteon</td>
<td>8 mg HS</td>
</tr>
<tr>
<td class="label">Modafinil</td>
<td>100-400 mg AM</td>
</tr>
<tr>
<td class="label">Medication</td>
<td>Concern</td>
</tr>
<tr>
<td class="label">Benzodiazepines (not clonazepam)</td>
<td>Fall risk, cognitive impairment</td>
</tr>
<tr>
<td class="label">Zolpidem</td>
<td>Fall risk, complex sleep behaviors</td>
</tr>
<tr>
<td class="label">High-dose dopaminergic agents</td>
<td>May worsen sleep architecture</td>
</tr>
<tr>
<td class="label">Anticholinergics</td>
<td>Cognitive side effects</td>
</tr>
<tr>
<td class="label">Sleep Medication</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">Clonazepam</td>
<td>Additive sedation</td>
</tr>
<tr>
<td class="label">Trazodone</td>
<td>Additive sedation; serotonergic effects minor</td>
</tr>
<tr>
<td class="label">Melatonin</td>
<td>Minimal interaction</td>
</tr>
<tr>
<td class="label">Gabapentin</td>
<td>Additive sedation</td>
</tr>
<tr>
<td class="label">Zolpidem</td>
<td>Metabolized by CYP3A4; potential interaction</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">6:00 PM</td>
<td>Dinner (light, low-protein to optimize levodopa absorption)</td>
</tr>
<tr>
<td class="label">7:00 PM</td>
<td>Limit fluids to reduce nocturia</td>
</tr>
<tr>
<td class="label">7:30 PM</td>
<td>Last caffeine-free beverage</td>
</tr>
<tr>
<td class="label">8:00 PM</td>
<td>Gentle stretching or relaxation</td>
</tr>
<tr>
<td class="label">8:30 PM</td>
<td>Sleep hygiene routine begin</td>
</tr>
<tr>
<td class="label">9:00 PM</td>
<td>Bedroom environment preparation</td>
</tr>
<tr>
<td class="label">9:30 PM</td>
<td>Melatonin 1-5 mg (if indicated)</td>
</tr>
<tr>
<td class="label">9:45 PM</td>
<td>Bedtime</td>
</tr>
<tr>
<td class="label">10:00 PM</td>
<td>Lights out</td>
</tr>
<tr>
<td class="label">Time</td>
<td>Activity</td>
</tr>
<tr>
<td class="label">6:30 AM</td>
<td>Wake time (consistent)</td>
</tr>
<tr>
<td class="label">6:45 AM</td>
<td>Bright light therapy 10,000 lux, 30 min</td>
</tr>
<tr>
<td class="label">7:00 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td class="label">7:30 AM</td>
<td>Physical activity (if scheduled)</td>
</tr>
<tr>
<td class="label">Factor</td>
<td>Rating</td>
</tr>
<tr>
<td class="label">Mechanistic Rationale</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Evidence Level</td>
<td>7/10</td>
</tr>
<tr>
<td class="label">Safety</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Accessibility</td>
<td>9/10</td>
</tr>
<tr>
<td class="label">Priority</td>
<td>High</td>
</tr>
</table>

Sleep disorders are among the most common and disabling non-motor symptoms in corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), often preceding motor symptoms by years and significantly impacting quality of life, disease progression, and caregiver burden.

Overview

Sleep disturbances in CBS and PSP differ from those in Parkinson's disease and other synucleinopathies. While rapid eye movement sleep behavior disorder (RBD) is common in synucleinopathies, CBS and PSP—predominantly 4R-tauopathies—show distinct sleep phenotypes characterized by:

• Sleep fragmentation with frequent nighttime awakenings
• Reduced REM sleep percentage and atonia abnormalities
• Circadian rhythm dysfunction with altered melatonin secretion
• Excessive daytime sleepiness (EDS)
• Insomnia difficulty with sleep onset and maintenance
• Sleep-disordered breathing including obstructive sleep apnea

Sleep Architecture Abnormalities in CBS/PSP

Polysomnographic Findings

polysomnography (PSG) studies reveal characteristic sleep architecture changes in CBS and PSP:

Key Pathophysiological Changes

REM Sleep Behavior Disorder in Tauopathies:

While RBD is classically associated with synucleinopathies (PD, MSA, DLB), emerging evidence shows RBD can occur in tauopathies, though less frequently. A meta-analysis found RBD in approximately 12% of PSP patients compared to 50-80% in PD[@iranzo2014]. The presence of RBD in a tauopathy patient may indicate:

• Mixed pathology (tau + synuclein co-pathology)
• Rigor mortis presentation in PSP
• Potential for underlying synucleinopathy despite negative seed amplification assay

Sleep spindles (NREM stage N2 hallmark) are reduced in both CBS and PSP, correlating with cognitive dysfunction. Reduced spindle density is associated with:

• Executive dysfunction
• Memory consolidation impairment
• Cortical thinning in frontal regions

PSP patients show flattened circadian rhythms with:

• Reduced amplitude of cortisol rhythm
• Altered body temperature rhythm
• Dysregulated melatonin secretion
• Phase advance of sleep timing

Specific Sleep Disorders in CBS/PSP

1. Insomnia

Prevalence: 60-80% of CBS/PSP patients

Characteristics:

• Difficulty initiating sleep
• Frequent nocturnal awakenings
• Early morning awakening
• Non-restorative sleep

• Motor rigidity and immobility causing discomfort
• Nocturnal dyspnea
• Depression and anxiety
• Medication effects (levodopa, MAO-B inhibitors)
• Neuroanatomical disruption of sleep-wake circuits

• Sleep hygiene optimization (see below)
• Melatonin 0.5-10 mg before bedtime
• Low-dose trazodone 25-100 mg
• Avoid benzodiazepines due to fall risk
• Address underlying depression/anxiety

2. Excessive Daytime Sleepiness

Prevalence: 30-50% of CBS/PSP patients

Characteristics:

• Unintended sleep episodes
• Difficulty maintaining alertness
• Sleep attacks unrelated to activity

• Nocturnal sleep fragmentation
• Neurodegeneration of wake-promoting neurons
• Medication effects (dopaminergic agents, clonazepam)
• Depression

• Optimize nocturnal sleep first
• Modafinil 100-400 mg (limited evidence)
• Caffeine 100-200 mg morning/early afternoon
• Light therapy for circadian entrainment
• Address sleep-disordered breathing

3. Sleep-Disordered Breathing

Prevalence: 40-60% of CBS/PSP patients

Types:

• Obstructive Sleep Apnea (OSA): Most common
• Central Sleep Apnea: More common in PSP
• Cheyne-Stokes Respiration: May occur with brainstem involvement

• Brainstem involvement in PSP
• Supraglottal airway collapse
• Position-dependent breathing
• Weight gain from reduced mobility

• Sleep study for diagnosis
• CPAP/BiPAP therapy (often poorly tolerated due to cognitive impairment)
• Weight management
• Positional therapy
• Oral appliances

4. REM Sleep Behavior Disorder

Prevalence: 10-15% in PSP (lower than synucleinopathies)

Characteristics:

• Dream enactment behaviors
• Sleep-related injuries
• REM without atonia on PSG

• Safety-proof bedroom environment
• Low-dose clonazepam 0.25-1 mg
• Melatonin 3-12 mg
• Remove bedside objects
• Pad floor near bed

5. Restless Legs Syndrome and Periodic Limb Movements

Prevalence: 15-25% in CBS/PSP

Characteristics:

• Uncomfortable sensations in legs at rest
• Urge to move legs
• Periodic limb movements during sleep

• Iron supplementation if ferritin <50 ng/mL
• Gabapentin 100-600 mg at bedtime
• Pramipexole (use with caution; may worsen RBD)
• Dopaminergic agents

6. Circadian Rhythm Disorders

Characteristics:

• Advanced sleep phase
• Irregular sleep-wake pattern
• 24-hour pattern disruption

• Bright light therapy 10,000 lux, 30 min morning
• Melatonin 0.5-5 mg 2-3 hours before desired bedtime
• Consistent sleep schedule
• Regular meal timing
• Physical activity timing

Sleep Assessment Protocol

Recommended Assessments

Diagnostic Workup

• Sleep pattern (bedtime, wake time, naps)
• Nocturnal symptoms (snoring, leg discomfort, movements)
• Daytime sleepiness (Epworth Sleepiness Scale)
• Dream enactment behaviors
• Medication review

• BMI, neck circumference
• Upper airway assessment
• Neurological examination (vertical gaze, parkinsonism signs)

• TSH (rule out hypothyroidism)
• Ferritin (if RLS suspected)
• Vitamin B12, folate
• Iron studies

Treatment Strategies

Non-Pharmacological Interventions

Sleep Hygiene Protocol

Circadian Entrainment

• Bright light therapy: 10,000 lux for 30 minutes each morning
• Melatonin: 0.5-5 mg 2-3 hours before desired bedtime
• Regular meal times: Breakfast, lunch, dinner at consistent times
• Physical activity: Morning preferred

Pharmacological Interventions

First-Line Treatments

Second-Line Treatments

Agents to Use with Caution

Device-Based Therapies

• CPAP/BiPAP: For sleep apnea (high failure rate due to tolerance)
• Light therapy device: 10,000 lux for morning entrainment
• White noise machines: For sleep continuity

Drug Interactions with Current Regimen

This patient is on levodopa and rasagiline (MAO-B inhibitor). Key sleep medication interactions:

Integrated Sleep Management Protocol

Evening Schedule for CBS/PSP Patient

Morning Protocol

Sleep and Disease Progression

Sleep disruption may accelerate tau pathology through multiple mechanisms:

Evidence in Tauopathies:

• PSP patients with poor sleep have faster disease progression
• Sleep quality correlates with CSF tau levels
• Sleep disruption is an independent risk factor for cognitive decline

Cross-Links to Related Pages

• [Sleep-Tau Clearance Mechanism](/mechanisms/sleep-tau-clearance)
• [Glymphatic System Enhancement](/therapeutics/glymphatic-system-enhancement)
• [Melatonin Therapy](/therapeutics/melatonin-therapy-neurodegeneration)
• [Circadian Rhythm in Neurodegeneration](/mechanisms/circadian-rhythm-neurodegeneration)
• [PSP Sleep Disorders](/mechanisms/psp-sleep-circadian-disorders)
• [CBS Circadian Dysfunction](/mechanisms/cbs-circadian-rhythm-dysfunction)
• [Polysomnography Overview](/diagnostics/polysomnography-overview)
• [REM Sleep Behavior Disorder](/diagnostics/rem-sleep-behavior-disorder-rbd)
• [Personalized Treatment Plan - Atypical Parkinsonism](/therapeutics/personalized-treatment-plan-atypical-parkinsonism)

NET Assessment

Patient Action Items

• [ ] Schedule polysomnography to assess sleep architecture
• [ ] Implement sleep hygiene protocol immediately
• [ ] Begin melatonin 0.5-5 mg 1-2 hours before bedtime
• [ ] Obtain bright light therapy device (10,000 lux)
• [ ] Consider actigraphy for circadian rhythm assessment
• [ ] Discuss RBD screening with sleep specialist
• [ ] Screen for sleep-disordered breathing
• [ ] Review medications for sleep-affecting side effects

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Sleep Spindle-Synaptic Plasticity Enhancement](/hypothesis/h-8d270062) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: CACNA1G
• [Biorhythmic Interference via Controlled Sleep Oscillations](/hypothesis/h-49791706) — <span style="color:#ffd54f;font-weight:600">0.54</span> · Target: GABRA1

• [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) &#x1f504;
• [Microglia-astrocyte crosstalk amplification loops in neurodegeneration](/analysis/SDA-2026-04-01-gap-009) &#x1f504;
• [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;